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Erratum
SUMO-1 Modification of Mdm2 Prevents Its Self-Ubiquitination and
Increases Mdm2 Ability to Ubiquitinate p53
In Buschmann et al. (Cell [101(7)], 753–762), we reported that Mdm2 is sumoylated and that
this event is important in Mdm2’s ability to mediate degradation of p53. In this study, we
identified Lysine 446 as the site of Mdm2 sumoylation and ubiquitination. Recent experiments
carried out in our laboratory, however, could not confirm Buschmann et al., finding that Mdm2
K446 is the site for Sumo conjugation to Mdm2. K446 is a primary site for Mdm2 self-
ubiquitination, explaining why this mutant is more potent than wt Mdm2 in its effects on p53,
and the nature of its prolonged half-life.
Whereas sumoylation of Mdm2 in vitro decreases its self-ubiquitination and increases its
ubiquitin ligase activity toward p53, this change can no longer be attributed to displacement
of ubiquitin with Sumo at the same site, but possibly to conformational based effects.
Given that K446 is a major ubiquitination site, but not the sumoylation site, greater targeting
of p53 for ubiquitination and degradation in vivo by K446 mutant could be now viewed as a
result of increased Mdm2 half-life and its E3 ligase activity. However, at present we cannot
exclude that sumoylation contributes to biological function(s) of Mdm2 independent of its
stability.
We deeply apologize for this error and its implications to the ongoing studies by our
colleagues, and we wish to thank the scientists who helped to clarify this matter over the
past few months.
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